The National Institutes of Health recently announced the first two of the RECOVER initiative’s long COVID clinical trials are now underway and open for enrollment.
The first study, called RECOVER-NEURO, will investigate interventions for long COVID cognitive dysfunction by testing therapies such as transcranial direct current stimulation. The second study, RECOVER-VITAL, will target viral persistence with its first intervention testing a long regimen of the antiviral nirmatrelvir/ritonavir (Paxlovid). Two other trials, RECOVER-SLEEP and RECOVER-AUTONOMIC, will also launch soon.